TNF receptor family members fused to the constant domain of immunoglobulin G have been widely used as immunoadhesins in basic in vitro and in vivo research and in some clinical applications. In this study, we assemble soluble, high avidity chimeric receptors on a pentameric scaffold derived from the coiled-coil domain of cartilage oligomeric matrix protein (COMP). The affinity of Fas and CD40 (but not TNFR-1 and TRAIL-R2) to their ligands is increased by fusion to COMP, when compared to the respective Fc chimeras. In functional assays, Fas:COMP was at least 20-fold more active than Fas:Fc at inhibiting the action of sFasL, and CD40:COMP could block CD40L-mediated proliferation of B cells, whereas CD40:Fc could not. In conclusion, members of the TNF receptor family can display high specificity and excellent avidity for their ligands if they are adequately multimerized.
Introduction
either in the membrane-bound form and / or as soluble cytokines after proteolytic processing. Their Ligands of the tumor necrosis factor (TNF) family receptors belong to a family of type I membrane are synthesized as homotrimeric type II membrane proteins characterized by repetitive cysteine-rich proteins, which fulfill their biological functions modules in their extracellular domains. Presently, 18 ligands and 22 receptors have been described, some of which are orphans while others For instance, Fas, TNF-R2, CD30 and GITR are involved in the control of T-cell receptor-mediated apoptosis of thymocytes and mature T cells (Russell tivation-induced cell death (Suda et al., 1993; Zheng et al., 1995; Amakawa et al., Hanabuchi et al., 1994; Dhein et al., 1995; Ju et al., 1996; Nocentini et al., 1997) . Soluble TNF acts as an 1995). Furthermore, in vivo analysis was performed inflammatory cytokine coordinating host defenses in by administration of recombinant RANK:Fc or by response to infection (Vassalli, 1992) . TRAIL /Apotransgenic expression of lymphotoxin b receptor:Fc 2L, whose expression can be induced on peripheral (Ettinger et al., 1996; Bachmann et al., 1999 ). blood T cells or on monocytes by interferons,
In the field of cytokine research, the use of mediates tumoricidal activity (Griffith et al., 1999;  chimeric soluble receptors is a promising alternative Kayagaki et al., 1999) . T-cell help via CD40L / CD40
to monoclonal antibodies to create efficient ininteraction is important for B cell survival, proliferhibitors: the simple fusion of receptors to an approation, immunoglobulin isotype switch and differenpriate oligomerization support yields blocking agents tiation (Laman et al., 1996; van Kooten and Ban- with high specificity and high affinity. Soluble chereau, 1997). Moreover, the CD40 signaling pathreceptors have the potential to block unknown way increases dendritic cell function and is therefore ligands and, when they do bind more than one implicated in antigen-specific T-cell responses in ligand, display a specificity distinct from that of an vivo (Grewal et al., 1995; Campbell et al., 1996) .
antibody. The activity of TNF-family members can be
In this study we demonstrate that the fusion of the regulated by soluble receptors, which are either gene extracellular domains of Fas and CD40 to the products on their own or result from proteolytic pentamerization domain of cartilage oligomeric maprocessing of membrane-bound receptors. For examtrix protein (COMP) (Malashkevich et al., 1996 ; ple, the soluble dimeric receptor OPG favors bone Terskikh et al., 1997) enhances their inhibitory formation by inhibiting RANKL / TRANCE / ODAF, activity towards their respective ligands as compared which is both a survival factor for dendritic cells and with classical Fc fusion proteins. an inducer of osteoclast differentiation and activation (Anderson et al., 1997; Simonet et al., 1997; Wong et al., 1997; Bucay et al., 1998; Lacey et al., 1998) .
2. Materials and methods Recombinant soluble receptors, which are classically produced as fusion proteins with the dimerizing 2.1. Materials constant domain of immunoglobulin G, are commonly used as specific inhibitors of their cognate ligands
The anti-Flag M2 monoclonal antibody and M2- (Chamow and Ashkenazi, 1996) . Indeed, high-affiniagarose was purchased from Sigma (Buchs, Switzerty inhibitors of TNF-family members are potentially land). Cell culture reagents were obtained from Life useful for treatment of disease where expression of Sciences (Basel, Switzerland). Molecular weight these ligands is disregulated. Chronic inflammation standards for gel permeation chromatography, HiTwith elevated TNF levels leads to diseases such as rap chelating and HiTrap Protein A columns were Crohn's disease or rheumatoid arthritis, and bothö btained through Pharmacia (Dubendorf, Switzerconditions can been improved by the administration land). Goat anti-mouse antibodies coupled to perof TNF-R2:Fc alone or in combination with other oxidase or to FITC were purchased from Jackson treatments (Stack et al., 1997; Weinblatt et al., 1999) . laboratories (La Roche, Switzerland). Anti-CD19 Ectopic expression of FasL has been shown to be antibody was obtained through Pharmingen. involved in toxic epidermal necrolysis, a severe, often lethal reaction to drugs that leads to massive keratinocyte cell death. Inhibition of the Fas-FasL 2.2. Cells system rapidly improves this condition (Viard et al., 1998) .
Murine B lymphoma A20 cells were maintained in Chimeric receptors have also been used for in DMEM containing 5% FCS and 50 mM b-mercapvitro studies to analyze the significance of FasL for toethanol. The human T lymphoblastoma Jurkat, the cytotoxic T lymphocyte (CTL) function and acJurkat subclone D 1.1 (kindly provided by Dr J. and a stop codon. The COMP oligomerization domethod (Pierce Chemical, Rockford, IL) using main was flanked by aa sequences GGCC and bovine serum albumin as standard and the purity was ARTPGGGS at the N and C-termini, respectively.
assessed by SDS-PAGE and Coomassie blue stainThe linker was present in all constructs and expresing. sion in the absence of the linker has not been tested. For Fc constructs, the hinge, CH2 and CH3 domains 2.6. Gel permeation chromatography and the stop codon of hIgG1 were cloned as a SalI/NotI cassette as previously described
The indicated amount of recombinant protein was .
loaded in a total volume of 200 ml onto a Superdex Stable HEK-293 derived cell lines for the production 200 HR 10 / 30 column (Pharmacia) and eluted at 0.5 of the recombinant proteins were established by ml / min in PBS with online recording of absorbance selection in 800 mg / ml of G418 with previously at 280 nm. Fractions (0.25 ml) were analyzed in published methods kDa respectively. in PBS containing 5% fetal calf serum (blocking buffer). When sCD40L was used, blocking buffer 2.9. BIAcore measurements was PBS containing 4% fat-free milk and 0.05% Tween-20. Competing Fc or COMP fusion proteins BIAcore measurements were carried out on CM5 were serially diluted in 100 ml of blocking buffer in carboxymethyldextran modified sensor chips (BIAthe presence or absence of 1 mg / ml of Protein A.
core AB, Uppsala, Sweden) at a flow-rate of 5 Ligands were added at constant concentration ml / min. The CM5 chips were activated with a 50-ml (sFasL: 2 mg / ml, 36 nM, sTNFa: 0.02 mg / ml, 0.36 pulse of a 1:1 mixture of N-ethyl-N9(3-dinM, sTRAIL: 0.1 mg / ml, 1.4 nM, sCD40L: 0.5 methylaminopropyl)carbodiimide:N-hydroxymg / ml, 9.2 nM; all in blocking buffer) and allowed succinimide. Six ml of a 100 mg / ml solution of M2 to bind for 1 h at 378C. Bound ligands were revealed anti-Flag monoclonal antibody in 10 mM NaHCO 3 with M2 anti-Flag antibody (1 mg / ml in blocking pH 5.5 was then passed over the activated surface. A buffer, 100 ml, 45 min, 378C), goat anti-mouse 50-ml pulse of 1 M ethanolamine-HCl deactivated antibody coupled to peroxidase (1:2000 in blocking the remaining N-hydroxysuccinimide esters. The buffer, 100 ml, 30 min, 378C) and o-phenylenediamamount of M2 immobilized using this procedure was ine hydrochloride (0.3 mg / ml in 50 mM citric acid, around 4600 response units. To analyze FasL-Fas-100 mM Na HPO , 0.01% H O ). Absorbance was :chimeras and TRAIL-TRAIL-R2:chimeras interac-2 4 2 2 measured at 490 nm. tion, a constant amount of flagged ligand was immobilized on the M2-modified surface. To achieve 2.8. Cytotoxic assays this, a 7-ml pulse of 2.5 mg / ml Flag-FasL or Flag-TRAIL was applied to the surface. This resulted in The cytotoxic assays were performed in 96-well binding of around 100 to 150 response units (these plates in a volume of 100 ml essentially as described conditions allowed minimum dissociation of ligands previously . Chimeric refrom the M2 surface, while allowing sufficient ceptors were serially diluted in medium containing subsequent receptor binding for the analysis). Bindthe amounts of cytotoxic ligands able to induce more ing of the receptor chimera was then analyzed by than 95% of cell death, as indicated in the figure 15-ml injections of purified receptor chimeras at legends. Where stated, Protein A was present at 1 concentrations ranging between 1 and 100 mg / ml, mg / ml. sFasL was always used in the presence of 1 corresponding to 100-150 response units. Associamg / ml of M2 and sTRAIL in the presence of 2 tion kinetics were measured for 3 min and dissociamg / ml of M2. No M2 was added in assays with tion kinetics for 3 to 5 min. The surface was sTNFa. Cell were added for a 16 h incubation and regenerated to a plain M2 surface by a 5-ml pulse of their viabilities were determined using the PMS / 50 mM citrate-HCl, pH 2. nM) and M2 antibody (final concentration: 1 mg / The CD40L Jurkat clone D 1.1 (5310 cells) ml)) was added and cells were incubated for another was incubated with 2 mg of CD40:COMP in FACS 16 h. The supernatant was taken off, fresh HAM buffer (PBS, 10% fetal calf serum and 0.02% NaN ).
3 (100 ml) was added and the viability assay PMS / Fas:COMP was used as a negative control. Re-MTS was performed as described under cytotoxic ceptor:COMP were detected with 1 mg of 9E10 assays.
anti-myc antibody followed by FITC-labeled goat anti-mouse antibody (1:100). Incubations were per-2.11. Activation-induced cell death formed for 20 min at 48C in 50 ml of FACS buffer.
Flat-bottom microtiter plates were coated with 2.14. B-cell proliferation assay anti-human CD3 TR66 (10 mg / ml) in PBS for 3 h at indicated in the figure legend and distributed to each rads). 10 purified CD19 cells were mixed with 10 2 well, then centrifuged (2003g, 3 min) and incubated CD19 autologous irradiated PBL in 120 ml of for 24 h at 378C. Cell viability (OD490) was medium containing sCD40L at 100 ng / ml (1.8 nM) measured as described for cytotoxic assays. Specific M2 antibody at 10 mg / ml plus or minus Protein A at cell protection (%) was calculated as follows: [(anti-1 mg / ml and the indicated concentrations of CD3 1 inhibitor) 2 (anti -CD3)] / [(control) 2 (anti -CD40:Fc or CD40:COMP. Cells were then cultured CD3)]3100.
for 72 h in 96-well plates, pulsed for 6 h with 3 3
[ H]thymidine (1 mCi / well) and harvested.
[ H]thyFasL (sFasL), although the level of protection (up to midine incorporation was monitored by liquid 50%) was extremely low considering that the estiscintillation counting. mated molar ratio of Fas:Fc to FasL was as high as 1000 in the assay (Fig. 1a, lower (Fig. 1b, upper panel) , it was and found that it eluted as a single peak with the clear that the high molecular weight Fas:Fc was an expected retention time (Fig. 1a, upper panel) . efficient antagonist of FasL cytotoxicity, whereas the Fas:Fc-containing fractions were able to partially remaining Fas:Fc that still eluted as a dimer only protect A20 cells exposed to a lethal dose of soluble conferred partial protection to cells despite its ten- fold higher concentration (Fig. 1b, lower panel) . affinity on metal-chelating columns or on Protein-A Taken together, these results indicate that the forma- (Figs. 2, 3a and b) . Fas and TRAIL-R2 were also tion of Fas:Fc aggregates substantially increases its joined to the C-terminal dimerization domain of the specific activity.
TNF family member osteoprotegerin (Receptor:≠N-OPG) .
Construction of novel oligomeric chimeras of
Receptors fused to COMP or CMP clearly oligo-TNF receptor family members merized, as indicated by their slow migration in polyacrylamide gels under non-reducing conditions We reasoned that an increase in the oligomeriza- (Fig. 3b) sFasL binding to coated Fas:Fc (Fig. 4a) . In accordcompetition ELISA, an important increase in affinity ance with this result, we measured a dissociation (30 fold) was observed for the pentamerized reconstant of 0.77 nM for the sFasL-Fas:COMP interceptor, whereas the effect was intermediate for action, which is around eight to nine times lower CD40:Fc / PA (eight fold) (Fig. 5a ). We next wonthan that found for Fas:Fc (Table 1) . On the majority dered whether CD40:COMP could also recognize of the cell lines tested, the inhibitory activity of membrane-bound CD40L. To this purpose, we used Fas:COMP was approximately ten-to 20-fold higher the Jurkat-derived cell line D1.1 that constitutively than that of dimeric Fas:Fc, whereas that of Fas:Fc expresses surface CD40L, to perform FACS staining aggregated in the presence of Protein A (Fas:Fc / PA) analysis using CD40 chimera as a probe. A signifiwas intermediate (Fig. 4b, 4e and data not shown) .
cant staining was observed with CD40:COMP inTwo cell lines (the murine A20 B lymphoma and the dicating that CD40:COMP was indeed able to bind human BJAB Burkitt lymphoma), although efficientto native, unprocessed CD40L (Fig. 5b) . To test the ly protected by Fas:COMP, were not or only very activity of the CD40 chimeras in a biological system, inefficiently protected by Fas:Fc (Fig. 4c) , even in we attempted to inhibit the CD40L-dependent prolifthe presence of a 20-fold excess of an irrelevant eration of human B cells costimulated with anti-B receptor:Fc (Fig. 4d) .
cell receptor. Neither CD40:Fc nor CD40:Fc / PA As expected, the activity of the dimeric Fas:≠N-could significantly prevent proliferation, even when OPG was similar to that of Fas:Fc (Fig. 4e) . Trimeric they were administered at high doses. In contrast, Fas:CMP inhibited sFasL-mediated lysis as efficient-CD40:COMP efficiently blocked proliferation, ally as Fas:Fc / PA but was about five times less ready at relatively low doses (Fig. 5c ). effective than Fas:COMP (Fig. 4e) . The inhibitory activity of Fas:COMP was as good or better than that of FasL-blocking mAb Nok-1, 4H9 and 4A5 3.5. Increased affinity of soluble chimeric (Kayagaki et al., 1995; Tanaka et al., 1996) .
receptors of the TNF-receptor family is not a The superior inhibitory activity of Fas:COMP general phenomenon compared to Fas:Fc was also evident on primary mouse hepatocytes (Fig. 4g ) or in a model system When the binding of the TRAIL-R2:Fc and for activation-induced cell death using anti-CD3 TRAIL-R2:COMP to sTRAIL was compared in the activated Jurkat cells (Fig. 4h) . In all experiments, competition ELISA assay, no significant differences Fas:Fc / PA yielded an intermediate level of protecin the affinities could be observed (Fig. 6a) . In tion. We next tested whether Fas:COMP would addition, the dissociation constants of the interacinhibit FasL expressed by CTLs. Killing of A20 cells tions of TRAIL with TRAIL-R2:COMP or TRAILin a 4-h assay depends uniquely on perforin and R2:Fc were not significantly different (Table 1) . FasL-dependent pathways, as CTLs deficient for These results are confirmed in a TRAIL inhibition both perforin and FasL have no effect on these cells assay on various cell lines, where all TRAIL- (Braun et al., 1996) . As expected, A20 cells were R2:chimeras were equally efficient ( Fig. 6b and c) . killed by both perforin-deficient CTLs and FasLThe same conclusion was obtained with TRAIL-R1, deficient CTLs (Fig. 4i) . Fas:Fc and Fas:COMP TRAIL-R3 and OPG, because their inhibitory acspecifically conferred some protection to cells extivities could not be increased upon aggregation with posed to perforin-deficient CTLs (Fig. 4i) . Surpris-PA ( Fig. 6d and data not shown). We also tested the ingly, there was no difference between Fas:Fc and efficiency of various TNF-R1 chimeric proteins at Fas:COMP and both inhibitors were partially active competing with TNFa binding to coated TNF-R1:Fc only when utilized at relatively high concentrations. and at inhibiting the cytotoxic effect of sTNFa. No differences were observed between TNF-R1:Fc, 3.4. CD40:COMP is a potent inhibitor of CD40L TNF-R1:Fc / PA and TNF-R1:COMP ( Fig. 6e and f) . These results indicate that increased oligomerization When the affinities of sCD40L to CD40:Fc, is beneficial for the activity of some but not all CD40:Fc / PA or CD40:COMP were compared by members of the TNF receptor family. 
Discussion
fully exploit the avidity potential inherent in the structure of the ligands. Cross-linked ligands, which Ligands of the TNF-family are trimeric and allow often display enhanced activity (Schneider et al., the binding of up to three receptors at their mono-1998), offer even more sites for high avidity receptor mer-monomer boundaries (Banner et al., 1993) .
binding. We have constructed fusion proteins of Recombinant dimeric receptors can therefore not various receptors to different dimeric (≠N-OPG), CTLs from perforin and gld mice were activated in a mixed lymphocyte culture (MLC) and cocultivated with [ Cr]-labeled A20 cells.
51
[ Cr] release in the supernatant was quantified after 4 h. trimeric (CMP), or pentameric (COMP) oligomericonsistent with the relatively high dissociation conzation supports and have compared them to restant that we have measured between Fas:Fc and ceptor:Fc fusion proteins. Inhibition of sFasL-inFasL (7 nM) and that reported for CD40L and duced apoptosis by these competitive inhibitors CD40:Fc (10-20 nM) (Hermann et al., 1993) . By increased as a function of their oligomerization level, comparison, the KD between monomeric TNF-R1 and the relative activities of the various inhibitors and TNFa is as low as 0.59 nM (Corti et al., 1994) , (expressed as the ratio of their respective IC ) and is close to 10 pM for TNFa and TNF-R1 on 50 remained relatively constant when measured on cells at 378C (Grell et al., 1998 they are multimerized. The affinities obtained are Fas:COMP was more efficient than Fas:Fc at above those usually observed for monoclonal antiblocking apoptosis mediated by membrane-bound bodies, and we could indeed show that Fas:COMP is FasL in a model of activation-induced cell death, but an equally or more potent inhibitor of sFasL than both reagents only partially blocked FasL-induced NOK-1 and other widely used FasL-blocking antiapoptosis mediated by CTLs. CTL action depends on bodies. both a close and tight contact with the target cell and on a transient and polarized activation of the cytotoxic machinery at the docking site (Bossi and Griffiths,
